In 2022, the company took a decisive turn, and what emerged was a different kind of company — one that didn’t stop at RNA manufacturing but went above and beyond to fix the weaknesses in how it’s designed, delivered, and produced.
Despite a “volatile” February due to uncertainty in the U.S. and abroad, CEO Marc Casper contends the company is “well positioned” to navigate the geopolitical environment.
